Mitral valve replacement The choice of which valve type to use depends upon the patient's age, medical condition, preferences with medication, and lifestyle. New Developments (2014 -2017): Transcatheter mitral valve replacement or TMVR involves human heart mitral valve replacement without recourse to open-heart surgery. TMVR treats mitral valve stenosis and/or mitral valve regurgitation leading to mitral insufficiency. TMVR, initially developed by the company Tendyne (a subsidiary of Jean Boulle Medtech Ltd) for open-heart high risk patients is expected to replace traditional mitral valve replacement surgery in the longer term. The Tendyne mitral valve is placed inside a beating heart via a transcatheter at
Mitral valve prolapse valve. The prevalence of MVP is estimated at 2–3% of the population. The condition was first described by John Brereton Barlow in 1966. In consequence, it may also be referred to as Barlow's syndrome, and was subsequently termed "mitral valve prolapse" by J. Michael Criley. Upon auscultation of an individual with mitral valve prolapse, a mid-systolic click, followed by a late systolic murmur heard best at the apex is common. The length of the murmur signifies the time period over which blood is leaking back into the left atrium, known as regurgitation. A murmur that lasts throughout the whole of